Abstract:The crosstalk between hepatic stellate cells (HSCs) and hepatic carcinoma cells contributes to hepatocellular carcinoma (HCC) progression, although the underlying mechanism is largely unknown. We found that activated HSCs upregulated nicotinamide (NAM) N-methyltransferase (NNMT) expression in hepatoma cells. NNMT regulates multiple metabolic pathways in the liver, and aberrantly high levels of NNMT in the HCC tissues were positively correlated with vascular invasion, serum HBV levels and distant metastasis in our study. Functional assays showed that NNMT promoted cell migration, invasion and metastasis in vitro and in vivo. Mechanistically, NNMT regulated the intracellular methylation potential which in turn altered histone H3K27 methylation pattern, resulting in the transcriptional activation of CD44. NNMT-mediated m6A modification of the CD44 mRNA resulted in the formation of the CD44v3 splice variant, while its product 1-MNA stabilized CD44 protein by preventing ubiquitin-mediated degradation. Finally, NNMT was also a target of statins which inhibited the metastatic ability of hepatoma cells. Taken together, our study provides evidence for the first time on the potential role of the NNMT/CD44v3 axis in regulating HCC metastasis, and presents NNMT as a promising prognostic biomarker and therapeutic target for HCC.Funding Statement: This study was supported by the National Natural Science Foundation of China (No.81672418 and 81871961, to Zhenyu Yin. No. 81802344,to Jie Li. No. 81572335,to Wenxiu Zhao) and the Xiamen Science and Technology Project of People-benefit (No. 3502Z20174089, to J.L.). Declaration of Interests: All of the authors have declared that no competing interests exist.Ethics Approval Statement: Specimen collection was performed after obtaining informed consent from each patient, and the utilization of the tumor materials for research purposes was carried out in accordance with the approved guidelines and approved by the Ethics Committee (No: 20111008) of Zhong Shan Hospital Xiamen University

NMI Promotes Hepatocellular Carcinoma Progression Via BDKRB2 and MAPK/ERK Pathway

MNS1 Promotes Hepatocarcinogenesis and Metastasis Via Activating PI3K/AKT by Translocating Β‐catenin and Predicts Poor Prognosis

NMI Inhibits Cancer Stem Cell Traits by Downregulating Htert in Breast Cancer

Downregulation of NMI promotes tumor growth and predicts poor prognosis in human lung adenocarcinomas

NNMT Involvement in CD44v3 Regulation Induced by Hepatic Stellate Cells Contributes to the Metastasis of Hepatocarcinoma Cells

High Expression of NME 1 Correlates with Progression and Poor Prognosis in Patients of Hepatocellular Carcinoma

NMI promotes cell proliferation through TGFβ/Smad pathway by upregulating STAT1 in colorectal cancer.

Elevated N‐methyltransferase Expression Induced by Hepatic Stellate Cells Contributes to the Metastasis of Hepatocellular Carcinoma Via Regulation of the CD44v3 Isoform

The miR-873/NDFIP1 axis promotes hepatocellular carcinoma growth and metastasis through the AKT/mTOR-mediated Warburg effect.

Overexpression of Bmi-1 Contributes to the Invasion and Metastasis of Hepatocellular Carcinoma by Increasing the Expression of Matrix Metalloproteinase (MMP)-2, MMP-9 and Vascular Endothelial Growth Factor Via the PTEN/PI3K/Akt Pathway

NMI: a potential biomarker for tumor prognosis and immunotherapy

NMI promotes tumor progression and gemcitabine resistance in pancreatic cancer via STAT3-IFIT3 axis

Mir-1204 Promotes Hepatocellular Carcinoma Progression Through Activating MAPK and C-Jun/ap1 Signaling by Targeting ZNF418

RMI2 is a prognostic biomarker and promotes tumor growth in hepatocellular carcinoma

MAP Kinase-Interacting Kinase 1 Promotes Proliferation and Invasion of Hepatocellular Carcinoma and is an Unfavorable Prognostic Biomarker.

N-Myc-interacting protein (NMI) negatively regulates epithelial-mesenchymal transition by inhibiting the acetylation of NF-κB/p65.

Suppression of Heterogeneous Nuclear Ribonucleoprotein C Inhibit Hepatocellular Carcinoma Proliferation, Migration, and Invasion via Ras/MAPK Signaling Pathway

NR1D2 Accelerates Hepatocellular Carcinoma Progression by Driving the Epithelial-to-Mesenchymal Transition

Mir-296-5p Suppresses EMT of Hepatocellular Carcinoma Via Attenuating NRG1/ERBB2/ERBB3 Signaling

microRNA-93-5p promotes hepatocellular carcinoma progression via a microRNA-93-5p/MAP3K2/c-Jun positive feedback circuit

Metabolism-Induced Tumor Activator 1 (Mita1), An Energy Stress-Inducible Long Noncoding Rna, Promotes Hepatocellular Carcinoma Metastasis